Insider · CIK 0001865125
Mika K Derynck
Files at ELVN (Enliven Therapeutics, Inc.). First filing Aug 6, 2026, latest Aug 6, 2026.
In brief
Mika K Derynck files SEC Form 4 as director at ELVN (Enliven Therapeutics, Inc.). Since Aug 6, 2026, Mika K Derynck has reported 0 open-market buys worth $0 and 1 open-market sell worth $9.6M, the latest filed on Aug 6, 2026.
A track record needs three past buys with six months of prices behind them; Mika K Derynck has 0, so none is measured yet.
The newest scored trade: sold $9.6M of ELVN on Aug 4, 2026, filed Aug 6, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $9.6M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ELVN: Enliven Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Enliven Therapeutics, Inc. | $9.6M 158,795 shares | -100% | +304% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | 158,795 0.22% of outstanding | $9.2M | Aug 4, 2026 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +87,373 | $2.48 | $217k | 87,373 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +27,567 | $25.28 | $697k | 114,940 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +23,364 | $14.85 | $347k | 138,304 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +20,491 | $22.47 | $460k | 158,795 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -158,795 | $60.21 | $9.6M | 0 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -87,373 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -27,567 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -23,364 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,491 | $0.00 | $0 | 0 | Aug 6, 2026 |
| Feb 12, 2026 | ELVN Enliven Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +17,126 | $0.00 | $0 | 17,126 | Feb 17, 2026 |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,491 | $0.00 | $0 | 20,491 | Feb 10, 2025 |
Questions about Mika K Derynck
Answered from the filings on this page, as of the latest one.
Is Mika K Derynck buying or selling?
In the last 12 months Mika K Derynck reported 0 open-market buys worth $0 and 1 open-market sell worth $9.6M on SEC Form 4; the latest was sold $9.6M of ELVN on Aug 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Mika K Derynck's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mika K Derynck has 0.
Where does Mika K Derynck file Form 4?
Mika K Derynck has filed Form 4 at ELVN (Enliven Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.